Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

Conditions: Atopic Dermatitis Interventions: Drug: SAR444656 (KT-474); Drug: Placebo Sponsors: Sanofi; Kymera Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials